Voomi Supply | $10,000,000 | (Mar 10, 2026)
Axiomatic_AI | $18,000,000 | (Mar 10, 2026)
Advocacy | $3,500,000 | (Mar 10, 2026)
Aulos Bioscience
United States
- Larkspur, California
- 01/08/2023
- Series A
- $20,000,000
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems towards killing tumor cells.
Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors.
The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- Industry Biotechnology Research
- Website https://aulosbio.com/
- LinkedIn https://www.linkedin.com/company/aulos-bioscience/
Crafting | $5,500,000 | (Mar 10, 2026)
Cylake | $45,000,000 | (Mar 10, 2026)
Augur | $15,000,000 | (Mar 10, 2026)
ANEUVO | $22,000,000 | (Mar 10, 2026)
DiligenceSquared (YC F25) | $5,000,000 | (Mar 10, 2026)
Mirai Robotics | $4,200,000 | (Mar 10, 2026)
Dify | $30,000,000 | (Mar 10, 2026)
Mega | $11,500,000 | (Mar 10, 2026)
Denki (YC F25) | $4,100,000 | (Mar 10, 2026)
KAST | $80,000,000 | (Mar 10, 2026)